For hospitalized patients already taking other proven COVID-19 drugs, pill further reduces chance of death Authors: KAI KUPFERSCHMIDT 3 MAR 2022 1:20 PM Baricitinib, an oral drug that dampens an overactive immune system and is commonly used by people with rheumatoid arthritis, reduced hospitalized COVID-19 patients’ risk of dying by 13%, investigators of the world’s […]
Authors Meiling Lee THURSDAY, MAR 03, 2022 – 07:40 PM The messenger RNA (mRNA) from Pfizer’s COVID-19 vaccine is able to enter human liver cells and is converted into DNA, according to Swedish researchers at Lund University. The researchers found that when the mRNA vaccine enters the human liver cells, it triggers the cell’s DNA, […]
Authors: Jules Gomes • ChurchMilitant.com • March 2, 2022 The mRNA from Pfizer’s COVID-19 vaccine converts into DNA within six hours of entering the body’s liver cells according to a groundbreaking study by Swedish researchers at Lund University. The explosive peer-reviewed research demolishes countless assertions by the “fact-checkers” and global health organizations. Fact-Checkers Caught UNICEF, for example, asserted that “mRNA vaccines are not […]
Authors: Markus Aldén 1,Francisko Olofsson Falla 1,Daowei Yang 1,Mohammad Barghouth 1,Cheng Luan 1,Magnus Rasmussen 2 andYang De Marinis 1,*1Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden2Infection Medicine, Department of Clinical Sciences, Lund University, 22362 Lund, Sweden Abstract Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a […]
Authors: Yan Xie, Evan Xu, Benjamin Bowe & Ziyad Al-Aly Nature Medicine (2022)Cite this article368k Accesses Citations14239 AltmetricMetrics Abstract The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of Veterans Affairs to build a cohort of […]
Authors: Elsevier As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to […]
Authors: Georgios Tsivgoulis, Lina Palaiodimou, Ramin Zand First Published December 8, 2020 Review Article Find in PubMed https://doi.org /10.1177/1756286420978004 Abstract Neurological manifestations are not uncommon during infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A clear association has been reported between cerebrovascular disease and coronavirus disease 2019 (COVID-19). However, whether this association is causal or incidental is […]
Authors: Elnaz Khani,aSajad Khiali,aSamineh Beheshtirouy,a and Taher Entezari-Malekia,b,∗ Eur J Pharmacol. 2021 Dec 5; 912: 174582.Published online 2021 Oct 19. doi: 10.1016/ j.ejphar.2021.174582 PMCID: PMC8524700PMID: 34678243 Abstract The acute loss of taste and smell following COVID-19 are hallmark symptoms that affect 20–85% of patients. However, the pathophysiology and potential treatments of COVID-19 smell and taste loss are not fully understood. We […]
Authors: Athanasia Printza,1,*Mihalis Katotomichelakis,2Konstantinos Valsamidis,1Symeon Metallidis,3Periklis Panagopoulos,4Maria Panopoulou,5Vasilis Petrakis,4 and Jannis Constantinidis1 J Clin Med. 2021 Mar; 10(5): 966.Published online 2021 Mar 2. doi: 10.3390/jcm10050966 PMCID: PMC7957474PMID: 33801170 Abstract A significant proportion of people infected with SARS-CoV-2 report a new onset of smell or taste loss. The duration of the chemosensory impairment and predictive factors of recovery are still unclear. We aimed […]
Authors. Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Omri Bodenheimer, M.Sc., Laurence Freedman, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D. Abstract BACKGROUND After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, the booster campaign in […]